# Systemic anti-inflammatory therapy to prevent or delay diabetic cataracts and treat post-surgical inflammation > **NIH NIH R01** · UNIVERSITY OF ALABAMA IN TUSCALOOSA · 2021 · $360,163 ## Abstract PROJECT SUMMARY Currently, surgical intervention is the only cure for cataracts, though this can be complicated in patients with diabetes. One of the most common postoperative complications in patients suffering from diabetes is persistent inflammation (uveitis) that can cause significant corneal edema, posterior synechia, and progression of diabetic retinopathy or neovascular glaucoma. There is substantial evidence that secondary cataract formation due to health conditions such as diabetes are associated with increased inflammation, oxidative stress, and sorbitol accumulation, along with covalent bonding of a protein or lipid molecule with a sugar molecule causing an increase in advanced glycosylation end products (AGE) formation that can cause significant damage to cells and tissues. The efforts to combat these effects using traditional drugs often leads to severe side effects outweighing the benefits. On the other hand natural compounds such as curcumin offer promise, but their progress is hampered due to lack of suitable dosage forms and poor bioavailability. In order to overcome inferior physicochemical and pharmacological attributes of curcumin we have prepared biodegradable nanosystems of polylactide-co-glycolide (PLGA) encapsulating curcumin (nCUR). These passively absorbed nCUR when given 8 mg/kg/day were significantly more effective than plain curcumin in delaying diabetic cataract in rodents, independent of glucose reduction. Despite the enhanced performance of passive nCUR, a significant dose remained unabsorbed in the intestine, indicating potential for further improvement through active-nanosystems. For the first time, we present a non-competitive active transport strategy to improve drug transport across biological barriers by developing carrier systems that have no equivalent in the world of competitive ligands. We hypothesize that transferrin receptor (TfR) mediated delivery across the intestinal barriers (IB) and blood ocular barriers (BOB) would significantly enhance the transport of the nanosystems making systemic anti-inflammatory therapy a reality. In this proposal, we will continue our studies on non-competitive active drug delivery strategy and understand how the systemic anti-inflammatory therapy will prevent or delay diabetic cataracts and manage post-surgical inflammation. To test this hypothesis, we propose the following specific aims: AIM #1. Establish the effectiveness of TfR in facilitating the transport of PLGA-GA NS across the IB and BOB in rat model. AIM #2. Establish the magnitude of desired or undesired effects in suitable rat models as a result of active transport. AIM #3. We will verify performance of this delivery strategy in a more man-like model. At the end of this study, we will have an effective systemic anti-inflammatory therapy to prevent or delay diabetic cataracts and treat post- surgical inflammation. ## Key facts - **NIH application ID:** 10246426 - **Project number:** 5R01EY028169-06 - **Recipient organization:** UNIVERSITY OF ALABAMA IN TUSCALOOSA - **Principal Investigator:** Ravikumar N Majeti - **Activity code:** R01 (R01, R21, SBIR, etc.) - **Funding institute:** NIH - **Fiscal year:** 2021 - **Award amount:** $360,163 - **Award type:** 5 - **Project period:** 2017-09-30 → 2024-08-31 ## Primary source NIH RePORTER: https://reporter.nih.gov/project-details/10246426 ## Citation > US National Institutes of Health, RePORTER application 10246426, Systemic anti-inflammatory therapy to prevent or delay diabetic cataracts and treat post-surgical inflammation (5R01EY028169-06). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10246426. Licensed CC0. --- *[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*